Cross-sectional analysis evaluates clinical phenotypes and environmental factors, suggesting machine learning may refine prediction strategies.
Introduction Parkinson's Disease (PD) represents the second most prevalent neurodegenerative disorder globally, with traditional assessment methods suffering from limitations including substantial inter-rater variability and inability to capture multifactorial complexity underlying disease progression. Methods Based on data from 500 Parkinson's disease patients, we integrated 7 standardized clinical phenotypes (excluding UPDRS to prevent data leakage) and 8 environmental exposure factors, compared 10 machine learning algorithms using 5-fold cross-validation, and applied SHAP interpretability analysis for transparent feature importance assessment. Results XGBoost with SMOTE sampling achieved clinically meaningful discriminative performance (AUC = 0.781, precision = 0.548, recall = 0.750) appropriate for screening applications. SHAP analysis revealed non-motor symptoms as the primary predictor (SHAP value = 2.76), followed by serum dopamine concentration (2.39) and age (2.16), while environmental factors demonstrated modest but statistically significant contributions. Discussion This proof-of-concept study developed an interpretable framework with methodological safeguards against data leakage, demonstrating promising screening potential with realistic performance expectations. However, the cross-sectional, single-center design limits generalizability, requiring external validation and longitudinal studies before clinical deployment.
No takes yet. Share an insight, caveat, or question.
Jin et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: